Sponsor content
326 result(s) found, displaying 31 to 40
-
Prescription medicine registrationActive ingredients: trastuzumab deruxtecan.
-
-
Australian public assessment report (AusPar)Truqap (capivasertib), in combination with fulvestrant, was approved for the treatment of adult patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine-based regimen.
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ARX-Ticagrelor ticagrelor 90 mg tablet blister pack.
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SIDAPVIA 10/100 dapagliflozin 10 mg (as propanediol monohydrate)/sitagliptin 100 mg (as phosphate monohydrate) film coated tablets blister pack.
-
Jan-2025Prescription medicine evaluationActive ingredient: acalabrutinib maleate monohydrate.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TRUQAP capivasertib 200 mg film coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TRUQAP capivasertib 160 mg film coated tablet blister pack.